AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19058133 — intervention group
Group type: EXPERIMENTAL
Intervention: levodopa/carbidopa/entacapone (LCE) 100/25/200
Number of subjects: 423
Study 19058133 — intervention group
Group type: COMPARATOR
Intervention: levodopa/carbidopa (LC) 100/25
Number of subjects: 423
Study 17894339 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole
Number of subjects: 69
Study 17894339 — intervention group
Group type: COMPARATOR
Intervention: Levodopa
Number of subjects: 69
Study 16189630 — intervention group
Group type: EXPERIMENTAL
Intervention: Kremezin (oral carbonaceous adsorbent) paired with conventional treatment (antihypertensive therapy and low-protein diet)
Number of subjects: 450
Study 16189630 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (antihypertensive therapy and low-protein diet) alone
Number of subjects: 450
Study 12202465 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (5 mg or more)
Number of subjects: 11
Study 12202465 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg or more)
Number of subjects: 11
Study 12202465 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (5 mg or greater)
Number of subjects: 11
Study 9036798 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cidofovir (5 mg/kg once weekly for 2 weeks, then 3 mg/kg once every 2 weeks)
Number of subjects: 64
Study 9036798 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cidofovir (5 mg/kg once weekly for 2 weeks, then 5 mg/kg once every 2 weeks)
Number of subjects: 64
Study 9036798 — intervention group
Group type: COMPARATOR
Intervention: Deferral group (treatment deferred until retinitis progressed)
Number of subjects: 64
Study 9036798 — intervention group
Group type: COMPARATOR
Intervention: Deferral group
Number of subjects: 64
Study 9036798 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cidofovir group
Number of subjects: 64
Study 9036798 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cidofovir group
Number of subjects: 64
Study 9036798 — intervention group
Group type: EXPERIMENTAL
Intervention: Cidofovir recipients
Number of subjects: 64
Study 9036798 — intervention group
Group type: EXPERIMENTAL
Intervention: Probenecid
Number of subjects: 64
Study 7621149 — intervention group
Group type: EXPERIMENTAL
Intervention: Bag-valve-mask (BVM)
Number of subjects: 30
Study 7621149 — intervention group
Group type: COMPARATOR
Intervention: Manually triggered oxygen powered breathing device (MTBD)
Number of subjects: 30
Study 3282815 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative plus postoperative irradiation
Number of subjects: 364
Study 3282815 — intervention group
Group type: COMPARATOR
Intervention: Postoperative irradiation alone
Number of subjects: 364
Study 31728742 — intervention group
Group type: EXPERIMENTAL
Intervention: Analytic priming task
Number of subjects: 178
Study 31728742 — intervention group
Group type: COMPARATOR
Intervention: Neutral priming task
Number of subjects: 178
Study 31181249 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant Feeding Beliefs Questionnaire (IFBQ)
Number of subjects: 803
Study 27558098 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponesimod regimen A (incremental dose increase from 2 to 20 mg in 9 steps)
Number of subjects: 32
Study 27558098 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponesimod regimen B (10 mg for 7 days followed by a single-dose administration of 20 mg)
Number of subjects: 32
Study 27558098 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponesimod regimen A
Number of subjects: 32
Study 27558098 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponesimod regimen B
Number of subjects: 32
Study 27558098 — intervention group
Group type: COMPARATOR
Intervention: Ponesimod (both regimens)
Number of subjects: 32
Study 25566560 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery with ring retractor
Number of subjects: 50
Study 25566560 — intervention group
Group type: COMPARATOR
Intervention: Surgery without ring retractor (control)
Number of subjects: 50
Study 23705963 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Qigong-based stress reduction program (BQSRP) for 4 weeks
Number of subjects: 50
Study 23705963 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 50
Study 21341919 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (8 mg/day)
Number of subjects: 34
Study 21341919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 19794998 — intervention group
Group type: EXPERIMENTAL
Intervention: Labor Assister (Baidy M‐420/Curexo, Inc., Seoul, Korea) with standard care
Number of subjects: 123
Study 19794998 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 123
Study 17124721 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg DiaPep277
Number of subjects: 30
Study 17124721 — intervention group
Group type: COMPARATOR
Intervention: 40 mg mannitol (placebo)
Number of subjects: 30
Study 14727273 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mL hyperbaric bupivacaine 0.5% (7.5 mg)
Number of subjects: 50
Study 14727273 — intervention group
Group type: COMPARATOR
Intervention: 4.2 mL hypobaric bupivacaine 0.18% (7.5 mg)
Number of subjects: 50
Study 11771827 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin, glucose, and potassium (GIK) infusion using an euglycemic clamp technique.
Number of subjects: 30
Study 11771827 — intervention group
Group type: COMPARATOR
Intervention: Control group (no GIK infusion).
Number of subjects: 30
Study 9316182 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH 4‐10 (1.25 mg intravenously, 30 minutes before testing)
Number of subjects: 16
Study 9316182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8487647 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human TNF (50 micrograms/m2)
Number of subjects: 6
Study 8487647 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 6
Study 2961815 — intervention group
Group type: EXPERIMENTAL
Intervention: HBIg (0.06 ml/kg) administered intramuscularly within 3 days after exposure, followed by a second dose 1 month later.
Number of subjects: 137
Study 2961815 — intervention group
Group type: EXPERIMENTAL
Intervention: HBIg (0.06 ml/kg) administered within 3 days followed by HB vaccine (HEVAC‐B Pasteur 10 micrograms) within 7 days after exposure.
Number of subjects: 137
Study 2961815 — intervention group
Group type: COMPARATOR
Intervention: Control group (no immuno-prophylaxis)
Number of subjects: 137
Study 2681882 — intervention group
Group type: EXPERIMENTAL
Intervention: L 841 A (vincristine + prednisone for remission induction, 18 Gy cranial irradiation + intrathecal methotrexate for CNS leukemia prophylaxis, maintenance with MTX iv alternating 5-day course of VCR + PDN + 6-mercaptopurine)
Number of subjects: 144
Study 2681882 — intervention group
Group type: EXPERIMENTAL
Intervention: L 841 B (asparaginase added)
Number of subjects: 144
Study 2681882 — intervention group
Group type: EXPERIMENTAL
Intervention: I 841 B (asparaginase added)
Number of subjects: 144
Study 2681882 — intervention group
Group type: EXPERIMENTAL
Intervention: I 841 C (asparaginase, Adriamycin, high-dose MTX 100 mg/kg)
Number of subjects: 144
Study 30912707 — intervention group
Group type: EXPERIMENTAL
Intervention: Television Commercials (TVCs)
Number of subjects: 1855
Study 30912707 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile messages for new mothers
Number of subjects: 1855
Study 30912707 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile messages for mothers of 4-7 year-olds
Number of subjects: 1855
Study 30912707 — intervention group
Group type: COMPARATOR
Intervention: Control TVC unrelated to handwashing
Number of subjects: 1855
Study 28196278 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon fibre frameworks
Number of subjects: 42
Study 28196278 — intervention group
Group type: COMPARATOR
Intervention: Metal frameworks (control group)
Number of subjects: 42
Study 28196278 — intervention group
Group type: COMPARATOR
Intervention: Comparison of bone resorption
Number of subjects: 42
Study 26600636 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nepafenac 0.1%
Number of subjects: 70
Study 26600636 — intervention group
Group type: COMPARATOR
Intervention: Topical flurbiprofen 0.03%
Number of subjects: 70
Study 24229823 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS) 0.5 mg once daily
Number of subjects: 202
Study 24229823 — intervention group
Group type: COMPARATOR
Intervention: Montelukast 4 to 5 mg once daily
Number of subjects: 202
Study 24229823 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS)
Number of subjects: 202
Study 24229823 — intervention group
Group type: COMPARATOR
Intervention: Montelukast
Number of subjects: 202
Study 21841719 — intervention group
Group type: EXPERIMENTAL
Intervention: Heel elevation device plus pressure‐redistributing support surface
Number of subjects: 239
Study 21841719 — intervention group
Group type: COMPARATOR
Intervention: Standard care (pressure‐redistributing support surface alone)
Number of subjects: 239
Study 19826135 — intervention group
Group type: EXPERIMENTAL
Intervention: Elesclomol 213 mg/m² plus paclitaxel 80 mg/m² (E + P)
Number of subjects: 81
Study 19826135 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel 80 mg/m² alone
Number of subjects: 81
Study 16731214 — intervention group
Group type: COMPARATOR
Intervention: Nortriptyline, fluoxetine, or placebo (double-blind methodology)
Number of subjects: 92
Study 16731214 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment (nortriptyline or fluoxetine)
Number of subjects: 92
Study 16731214 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 92
Study 15589019 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 0
Study 15589019 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 0
Study 15589019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11506113 — intervention group
Group type: EXPERIMENTAL
Intervention: Train-of-four stimuli at 15-s intervals for 25 min (Group 1)
Number of subjects: 30
Study 11506113 — intervention group
Group type: EXPERIMENTAL
Intervention: Single stimuli at 1.0 Hz for 10 min (Group 2)
Number of subjects: 30
Study 11506113 — intervention group
Group type: EXPERIMENTAL
Intervention: 50-Hz tetanus of 5 seconds' duration before calibration (Group 3)
Number of subjects: 30
Study 9525302 — intervention group
Group type: EXPERIMENTAL
Intervention: smoking intervention plus bronchodilator
Number of subjects: 5887
Study 9525302 — intervention group
Group type: COMPARATOR
Intervention: smoking intervention plus placebo
Number of subjects: 5887
Study 9525302 — intervention group
Group type: COMPARATOR
Intervention: no intervention
Number of subjects: 5887
Study 9525302 — intervention group
Group type: EXPERIMENTAL
Intervention: smoking intervention
Number of subjects: 5887
Study 8355460 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) therapy
Number of subjects: 35
Study 8355460 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated hemodialysis patients)
Number of subjects: 35
Study 3611686 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk tolerance test (500 ml milk)
Number of subjects: 40
Study 3611686 — intervention group
Group type: COMPARATOR
Intervention: Lactose tolerance test
Number of subjects: 40
Study 29150845 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbitol 3.2 g
Number of subjects: 16
Study 29150845 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbitol 10.2 g
Number of subjects: 16
Study 29150845 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbitol 13.4 g
Number of subjects: 16
Study 29150845 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine 300 mg alone
Number of subjects: 16
Study 26091986 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone call scenario
Number of subjects: 19
Study 26091986 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient discomfort scenario
Number of subjects: 19
Study 26091986 — intervention group
Group type: COMPARATOR
Intervention: Overall association
Number of subjects: 19
Study 24269547 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen
Number of subjects: 20
Study 24269547 — intervention group
Group type: COMPARATOR
Intervention: No supplemental oxygen
Number of subjects: 20
Study 24269547 — intervention group
Group type: EXPERIMENTAL
Intervention: Capnography monitoring
Number of subjects: 20
Study 22112014 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus 1% cream
Number of subjects: 40
Study 22112014 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 40
Study 22112014 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus 1% cream (subgroup analysis)
Number of subjects: 40
Study 22112014 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream (subgroup analysis)
Number of subjects: 40
Study 20403940 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (LGG) at a dose of 10^9 colony-forming units in 100 mL of a fermented milk product (LGG group, n = 376)
Number of subjects: 742
Study 20403940 — intervention group
Group type: COMPARATOR
Intervention: Placebo (placebo group, n = 366)
Number of subjects: 742
Study 17555526 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of antiepileptic drugs (CBZ)
Number of subjects: 150
Study 17555526 — intervention group
Group type: COMPARATOR
Intervention: Nonwithdrawal group (control)
Number of subjects: 150
Study 16640188 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive rehabilitation (TH-I) with earlier coordinative training due to unrestricted weight-bearing
Number of subjects: 45
Study 16640188 — intervention group
Group type: COMPARATOR
Intervention: Conservative rehabilitation (TH-C)
Number of subjects: 45
Study 16640188 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (TH-I and TH-C)
Number of subjects: 45
Study 14624771 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐hGH 0.05 mg/kg/day (high dose)
Number of subjects: 31
Study 14624771 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐hGH 0.025 mg/kg/day (low dose)
Number of subjects: 31
Study 14624771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 10418696 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLU)
Number of subjects: 55
Study 10418696 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (DMI)
Number of subjects: 55
Study 10418696 — intervention group
Group type: COMPARATOR
Intervention: Control (TRP-free drink)
Number of subjects: 55
Study 7719072 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy with prednisolone 1% eyedrops
Number of subjects: 30
Study 7719072 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy with indomethacin 1% eyedrops
Number of subjects: 30
Study 7719072 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with prednisolone 1% + indomethacin 1% eyedrops
Number of subjects: 30
Study 2043017 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine hydrochloride (5-mg capsules, three times daily for 5 months)
Number of subjects: 31
Study 2043017 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine hydrochloride
Number of subjects: 31
Study 2043017 — intervention group
Group type: COMPARATOR
Intervention: Placebo (randomly assigned for 1 month)
Number of subjects: 31
Study 6167116 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% benzoyl peroxide preparation
Number of subjects: 0
Study 30861337 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK3389404 (10 mg, 30 mg, 60 mg, 120 mg single doses)
Number of subjects: 42
Study 30861337 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK3389404 (30 mg, 60 mg, 120 mg multiple doses, once weekly for 4 weeks)
Number of subjects: 42
Study 30861337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 29890048 — intervention group
Group type: EXPERIMENTAL
Intervention: ART initiated regardless of CD4 count (intervention arm)
Number of subjects: 900
Study 29890048 — intervention group
Group type: COMPARATOR
Intervention: ART initiated according to national guidelines (control arm)
Number of subjects: 900
Study 27821142 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy (NPWT)
Number of subjects: 0
Study 27821142 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no NPWT)
Number of subjects: 0
Study 24198300 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention cohort (high ACR tertile)
Number of subjects: 400
Study 22217118 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention (password-protected website with information about colorectal cancer and screening options)
Number of subjects: 391
Study 22217118 — intervention group
Group type: COMPARATOR
Intervention: Printed format (control group)
Number of subjects: 391
Study 19395585 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib 50 mg alone
Number of subjects: 24
Study 19395585 — intervention group
Group type: COMPARATOR
Intervention: Famotidine 40 mg given 10 hours before dasatinib
Number of subjects: 24
Study 19395585 — intervention group
Group type: COMPARATOR
Intervention: Antacid (Maalox) 2 hours before dasatinib
Number of subjects: 24
Study 19395585 — intervention group
Group type: COMPARATOR
Intervention: Antacid (Maalox) coadministered with dasatinib
Number of subjects: 24
Study 17224718 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (400 mg daily)
Number of subjects: 12
Study 17224718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 15131729 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application using a body wash containing 0.15% vitamin E and 0.10% vitamin E acetate
Number of subjects: 0
Study 15131729 — intervention group
Group type: COMPARATOR
Intervention: Dietary supplementation with 400 IU alpha-tocopherol
Number of subjects: 0
Study 11669085 — intervention group
Group type: EXPERIMENTAL
Intervention: Mistletoe preparation (Abnobaviscum Quercus) injected subcutaneously three times a week for 6 months
Number of subjects: 25
Study 11669085 — intervention group
Group type: COMPARATOR
Intervention: Pre-treatment observation for 6 months
Number of subjects: 25
Study 9536925 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg once daily)
Number of subjects: 10
Study 9536925 — intervention group
Group type: COMPARATOR
Intervention: Atrial natriuretic peptide infusion (0.01 microgram min-1 kg-1)
Number of subjects: 10
Study 7665687 — intervention group
Group type: EXPERIMENTAL
Intervention: HHV‐6 detected in cervixes
Number of subjects: 72
Study 7665687 — intervention group
Group type: EXPERIMENTAL
Intervention: HHV‐7 detected in cervixes
Number of subjects: 72
Study 7665687 — intervention group
Group type: EXPERIMENTAL
Intervention: HHV‐6 and HHV‐7 co-detection
Number of subjects: 72
Study 7665687 — intervention group
Group type: EXPERIMENTAL
Intervention: HHV‐6 variant type
Number of subjects: 72
Study 2469243 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU)
Number of subjects: 30
Study 2469243 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 795433 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflucortolone valerate cream and ointment (0.1%)
Number of subjects: 925
Study 795433 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflucortolone valerate fatty ointment (0.1%)
Number of subjects: 925
Study 795433 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflucortolone valerate (all forms)
Number of subjects: 925
Study 795433 — intervention group
Group type: COMPARATOR
Intervention: Fluocortolone (Ultralan)
Number of subjects: 925
Study 30745078 — intervention group
Group type: EXPERIMENTAL
Intervention: lidocaine 2% with epinephrine
Number of subjects: 112
Study 30745078 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 0.5% with epinephrine
Number of subjects: 112
Study 30745078 — intervention group
Group type: COMPARATOR
Intervention: lidocaine 2%
Number of subjects: 112
Study 30745078 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine 0.5%
Number of subjects: 112
Study 28685560 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctor Tecar TherapyTM
Number of subjects: 60
Study 28685560 — intervention group
Group type: COMPARATOR
Intervention: Laser therapy
Number of subjects: 60
Study 25975558 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhenggan Tang decoction
Number of subjects: 66
Study 25975558 — intervention group
Group type: COMPARATOR
Intervention: Inosine tablets and vitamin C (Control)
Number of subjects: 66
Study 23815742 — intervention group
Group type: EXPERIMENTAL
Intervention: Benidipine (2 mg daily, increased to 8 mg daily)
Number of subjects: 104
Study 23815742 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (2.5 mg daily, increased to 10 mg daily)
Number of subjects: 104
Study 21528596 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcichew D3 tablets and acupoint catgut embedding
Number of subjects: 105
Study 21528596 — intervention group
Group type: COMPARATOR
Intervention: Calcichew D3 tablets (oral administration)
Number of subjects: 105
Study 21528596 — intervention group
Group type: COMPARATOR
Intervention: Calcichew D3 tablets and Xianling Gubao capsule (oral administration)
Number of subjects: 105
Study 19210013 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Aid (DA)
Number of subjects: 214
Study 19210013 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 214
Study 16845799 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuously slow intravenous arsenic trioxide (As2O3) infusion regimen for 24 hours at an infusion rate of 8 drips per minute, total infusion duration of about 18-21 hours daily, daily dosage of 0.16 mg/kg
Number of subjects: 75
Study 16845799 — intervention group
Group type: COMPARATOR
Intervention: Routine regimen with arsenic trioxide (As2O3) infusion at an infusion rate of 45-55 drips per minute, total infusion duration of about 2-3 hours daily, daily dosage of 0.16 mg/kg
Number of subjects: 75
Study 16845799 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuously slow intravenous arsenic trioxide (As2O3) infusion regimen
Number of subjects: 75
Study 16845799 — intervention group
Group type: COMPARATOR
Intervention: Routine regimen with arsenic trioxide (As2O3) infusion
Number of subjects: 75
Study 14665897 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant use of sildenafil (100 mg) and a vacuum entrapment device (VED)
Number of subjects: 161
Study 14665897 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil (100 mg)
Number of subjects: 161
Study 14665897 — intervention group
Group type: COMPARATOR
Intervention: Vacuum entrapment device (VED)
Number of subjects: 161